As for other agents, [44–46] such as proteasome- and mTOR-inhibitors, BTK inhibition also led to clinical responses supported by IgM monoclonal component reduction and hemoglobin level increase even in absence of any reduction of BM tumor infiltration, thus suggesting the ability of these novel agents to possibly act indirectly through an effect on the BM milieu. This evidence concerns the gene CD40LG and neoplasm.